Last reviewed · How we verify
Universidad de Colima — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Probiotic (Lactobacillus reuteri Prodentis | Probiotic (Lactobacillus reuteri Prodentis | marketed | Probiotic | Dentistry / Oral Health | ||
| Oral Electrolytes | Oral Electrolytes | marketed | ||||
| ketamine sedation versus midazolam sedation | ketamine sedation versus midazolam sedation | phase 3 | Anesthetic | NMDA receptor | Anesthesiology |
Therapeutic area mix
- Anesthesiology · 1
- Dentistry / Oral Health · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- BioBalance Corporation · 1 shared drug class
- Biocodex · 1 shared drug class
- CD Pharma India Pvt. Ltd. · 1 shared drug class
- CHU de Quebec-Universite Laval · 1 shared drug class
- Chuncheon Sacred Heart Hospital · 1 shared drug class
- Dow University of Health Sciences · 1 shared drug class
- Express Specialty Pharmacy · 1 shared drug class
- Aga Khan University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Universidad de Colima:
- Universidad de Colima pipeline updates — RSS
- Universidad de Colima pipeline updates — Atom
- Universidad de Colima pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Universidad de Colima — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidad-de-colima. Accessed 2026-05-16.